2018
Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber AL, Davidoff AJ, Sedghi T, Gross CP. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Research And Treatment 2018, 172: 453-461. PMID: 30099634, PMCID: PMC6193824, DOI: 10.1007/s10549-018-4919-3.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryBreast cancer mortalitySubsequent mastectomyCancer mortalityPre-operative MRIBreast cancerSubgroup analysisStage I/II breast cancerEnd Results-Medicare datasetPreoperative breast magnetic resonanceEarly-stage breast cancerMagnetic resonance imaging useReceipt of radiotherapyBreast magnetic resonanceClinical outcomesCox regressionResultsOur sampleImproved outcomesAdjusted ratesMRI useOlder womenLower riskMastectomyImaging useRadiotherapy
2017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volume
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factorsPreoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ. Breast Cancer Research And Treatment 2016, 158: 139-148. PMID: 27287780, PMCID: PMC5554869, DOI: 10.1007/s10549-016-3858-0.Peer-Reviewed Original ResearchConceptsContralateral breast cancerMagnetic resonance imagingPreoperative magnetic resonance imagingDuctal carcinomaMRI usePreoperative breast magnetic resonance imagingEnd Results-Medicare datasetInvasive contralateral breast cancerOccult contralateral breast cancerResonance imagingSynchronous contralateral breast cancerImpact of MRIStage-specific incidence ratesPreoperative MRI useBreast magnetic resonance imagingBreast cancer occurrenceCBC eventsCBC ratesCumulative incidencePropensity score approachIncidence rateInvasive diseaseBreast cancerCancer occurrenceOlder women
2015
Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. Journal Of Clinical Oncology 2015, 34: 321-328. PMID: 26628465, PMCID: PMC4872032, DOI: 10.1200/jco.2015.62.9741.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsFemaleHumansMagnetic Resonance ImagingPreoperative CareSEER ProgramUnited StatesConceptsContralateral breast cancerPreoperative magnetic resonance imagingMagnetic resonance imagingBreast cancerCBC eventsMRI useOlder womenPreoperative breast magnetic resonance imagingOccult contralateral breast cancerResonance imagingStage IIEarly-stage breast cancerPreoperative MRI useBreast magnetic resonance imagingBreast cancer occurrenceSEER-Medicare databaseImpact of detectionDetection rateCumulative incidenceCancer occurrenceStage ICancerPropensity scoreWomenPatientsThe Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapy
2014
Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2013
For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery
Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2013, 155: 776-788. PMID: 24787104, PMCID: PMC4008843, DOI: 10.1016/j.surg.2013.12.009.Peer-Reviewed Original ResearchConceptsHospital ownership statusBreast-conserving operationsBreast-conserving surgeryUse of brachytherapyRadiation therapyOperative careBreast cancerMedicare beneficiariesOverall useReceipt of brachytherapyAdjuvant radiation therapyInvasive breast cancerFemale Medicare beneficiariesGreater overall useYears of ageShort life expectancyRetrospective studyRT modalityProfit hospitalsExpensive modalityOlder womenBrachytherapy useBreast brachytherapyHospitalBrachytherapyVariation in Receipt of Radiation Therapy After Breast-conserving Surgery
Feinstein AJ, Soulos PR, Long JB, Herrin J, Roberts KB, Yu JB, Gross CP. Variation in Receipt of Radiation Therapy After Breast-conserving Surgery. Medical Care 2013, 51: 330-338. PMID: 23151590, PMCID: PMC3596448, DOI: 10.1097/mlr.0b013e31827631b0.Peer-Reviewed Original ResearchConceptsUse of RTShort life expectancyRadiation therapyBreast cancerLife expectancyPrimary surgeonStage I breast cancerEarly-stage breast cancerRadiation oncologist densityAdjuvant radiation therapyI breast cancerReceipt of radiationBreast-conserving surgeryImpact of physiciansHierarchical logistic regression modelsLogistic regression modelsLonger life expectancyLE patientsRetrospective cohortLE groupOlder womenPatientsTreatment ratesWomenCancer
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differencesThe Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications
Roberts KB, Soulos PR, Herrin J, Yu JB, Long JB, Dostaler E, Gross CP. The Adoption of New Adjuvant Radiation Therapy Modalities Among Medicare Beneficiaries With Breast Cancer: Clinical Correlates and Cost Implications. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: 1186-1192. PMID: 23182396, PMCID: PMC3606652, DOI: 10.1016/j.ijrobp.2012.10.009.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyRadiation therapy modalitiesRadiation therapy costsBreast cancerRadiation therapyTherapy modalitiesTherapy costsBrachytherapy useRadiation oncologistsEnd Results-Medicare databaseConventional external beam radiation therapyAdoption of intensityBreast-conserving surgeryRadiation therapy useUse of IMRTBeam radiation therapyNewer radiation therapy modalitiesHierarchical logistic regressionHospital-based facilitiesTherapy useClinical factorsClinical correlatesTreatment optionsTreatment choicePhysician preferencePatterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal Of Clinical Oncology 2012, 30: 4302-4307. PMID: 23091103, PMCID: PMC3675700, DOI: 10.1200/jco.2012.43.5297.Peer-Reviewed Original ResearchConceptsWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsEarly-stage breast cancerNational treatment patternsPercent of patientsShort-term complicationsBreast-conserving surgeryNational Medicare populationComplication rateTreatment patternsAge 66Breast cancerReferral regionsMedicare populationPatterns of useComplicationsMedicare beneficiariesTreatment groupsClinical practiceBreast brachytherapyBrachytherapyInstrumental variable analysisAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatment
2003
Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices
Singh HS, Roberts KB, Yue N, Nath R, Song GH, Azimi N, Pfau S. Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices. Cardiovascular Revascularization Medicine 2003, 4: 126-132. PMID: 14984712, DOI: 10.1016/s1522-1865(03)00183-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBlood Vessel Prosthesis ImplantationBrachytherapyConnecticutCoronary AngiographyCoronary Artery BypassCoronary RestenosisCoronary StenosisEquipment DesignFamily PracticeFemaleFollow-Up StudiesHospital MortalityHumansMaleMiddle AgedRadiation DosageReoperationRetrospective StudiesStentsTreatment OutcomeConceptsMajor adverse cardiac eventsStent restenosisAverage treatment ageEffectiveness of brachytherapyAdverse cardiac eventsSingle institution experienceMinimal lumen diameterRandomized clinical trialsLesion-specific characteristicsSpectrum of patientsMACE rateHospital deathCardiac eventsRenal failureUnstable anginaClinical outcomesCoronary lesionsTreatment failureInstitution experienceFrequent presentationInterventional therapyClinical trialsGeneral populationInterventional practicePatients
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1998
Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3
1996
Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
Fishman D, Roberts K, Chambers J, Kohorn E, Schwartz P, Chambers S. Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium. Gynecologic Oncology 1996, 61: 189-196. PMID: 8626131, DOI: 10.1006/gyno.1996.0123.Peer-Reviewed Original ResearchConceptsClinical stage IOperable patientsInoperable patientsIntercurrent diseaseStage IRadiation therapyMedian survivalEndometrioid carcinomaMore deathsMedian disease-free intervalExclusive radiation therapyMedically Inoperable PatientsStage I groupCancer-specific survivalDisease-free intervalStage II diseaseOverall survival rateShorter overall survivalOperable diseaseOperable groupEndometrial cancerOverall survivalSuch patientsShorter survivalClinical stage
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program